The benefits of taking the new diabetes/weight loss medications
John Lennon sang: "You say you want a revolution/Well, you know/We all want to change the world." Well, you could say the revolutionary new weight loss and diabetes management medications semaglutide (Ozempic) and tirzepatide (Mounjaro) are doing just that: Changing the world of disease management in ways that weren't imagined when semaglutide was approved in 2017. These days, it's approved for managing Type 2 diabetes, weight loss and to reduce the risk of cardiovascular complications -- and research is revealing it (and probably its nephew Mounjaro) has even more powers to improve your well-being.
Semaglutide reduces the risk of stroke and heart attack in people with heart failure by 28% and causes a 24% reduction in cardiovascular-related death; lowers the risk of kidney failure in folks with Type 2 diabetes and kidney disease by 24%; and if you have Type 2 diabetes, it cuts the chance of developing 10 obesity-related cancers. There's even preliminary research showing it may help treat Parkinson's and Alzheimer's.
Add to all that the latest findings: Obese folks without Type 2 diabetes who took semaglutide during the COVID-19 epidemic had a 33% lower risk of dying from COVID-19 than those not taking the medication.
So, if you have Type 2 diabetes or obesity, talk to your doctor about the benefits of taking semaglutide. (Risks vary from minor gastrointestinal upset to mood changes, ongoing stomach pain, and rapid heartbeat.) For more support on losing weight or managing Type 2 diabetes, read Dr. Oz's blogs on iHerb.com/blog and Dr. Mike's book "What to Eat When."
Dr. Mike Roizen is the founder of www.longevityplaybook.com, and Dr. Mehmet Oz is global advisor to www.iHerb.com, the world's leading online health store. Roizen and Oz are chief wellness officer emeritus at Cleveland Clinic and professor emeritus at Columbia University, respectively. Together they have written 11 New York Times bestsellers (four No. 1's).
(c)2024 Michael Roizen, M.D.
Distributed by King Features Syndicate, Inc.
(c) 2024 Michael Roizen, M.D. Distributed by King Features Syndicate, Inc.
Comments